Abstract
Advances in multimodality therapy have improved the survival rates of pediatric sarcomas over the last 40 years, with current rates over 65 %. However, the advances have not been equal, and patients with metastatic and relapsed disease continue to have a poor prognosis. This review focuses on the epidemiology, prognostic factors, treatment, and survival of the three most common pediatric sarcomas: osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma. It highlights a new collaboration to study osteosarcoma, recent advances in Ewing sarcoma treatment with increased intensity of chemotherapy timing, and advances in low-risk and high-risk rhabdomyosarcoma treatment. Additionally, it discusses the common treatment-related sequelae encountered in survivors. Sarcoma survivors have increased functional impairment and activity limitations compared with healthy controls and other cancer survivors, emphasizing the need to increase research in these areas in order to improve future physical functioning and quality of life.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
